Cover Image
市場調查報告書

發炎性腸道疾病(IBD):開發中產品分析

Inflammatory Bowel Disease - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213103
出版日期 內容資訊 英文 1025 Pages
訂單完成後即時交付
價格
Back to Top
發炎性腸道疾病(IBD):開發中產品分析 Inflammatory Bowel Disease - Pipeline Review, H2 2015
出版日期: 2015年12月31日 內容資訊: 英文 1025 Pages
簡介

發炎性腸道疾病(IBD)泛指的是伴隨消化道的反疫反應或發炎,慢性或復發性疾病。常見有腹部痙攣、腹痛、(伴隨出血、體重減少、食慾不振、發熱的)腹瀉等徵兆和症狀。致病要素有年齡,家族病史,抽煙,部分止痛藥等。治療法包含了皮質類固醇,免疫抑制劑,抗生素,止痛藥等。

本報告提供發炎性腸道疾病(IBD)的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

發炎性腸道疾病(IBD)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的的開發企業

  • Ingelheim GmbH
  • Amgen Inc.
  • Sanofi
  • Athersys, Inc.
  • GlaxoSmithKline plc
  • Biotec Pharmacon ASA
  • Emergent BioSolutions Inc.
  • 武田藥品工業
  • BioLineRx, Ltd.
  • TiGenix NV
  • 飛鳥製藥
  • Eisai
  • 田邊三菱製藥
  • 小野藥品工業
  • Paratek Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • 4SC AG
  • Addex Therapeutics
  • AlbireoPharma
  • iCo Therapeutics Inc.
  • Basilea Pharmaceutica AG
  • Compugen Ltd.
  • Pluristem Therapeutics Inc.
  • Galapagos NV
  • Synta Pharmaceuticals Corp.
  • Sareum Holdings plc
  • Sucampo Pharmaceuticals, Inc.
  • MetrioPharm AG
  • Advinus Therapeutics Ltd.
  • Affimed Therapeutics AG
  • Axxam SpA
  • ActogeniX NV
  • Omni Bio Pharmaceutical Inc.
  • Am-Pharma B.V.
  • Jenrin Discovery, Inc.
  • Upsher-Smith Laboratories, Inc.
  • Ventria Bioscience 73
  • Aquinox Pharmaceuticals Inc. 74
  • Argos Therapeutics, Inc. 75
  • Catabasis Pharmaceuticals, Inc. 76
  • Opsona Therapeutics Ltd. 77
  • Inotek Pharmaceuticals Corporation 78
  • Zealand Pharma A/S 79
  • Giuliani S.p.A. 80
  • Vitae Pharmaceuticals, Inc.
  • kyorin製藥
  • Synergy Pharmaceuticals, Inc.
  • Ensemble Discovery Corporation
  • Celsus Therapeutics Plc
  • Medestea Research & Production S.p.A.
  • Antibe Therapeutics, Inc.
  • Nephrx Corporation
  • SunTen Phytotech Co., Ltd.
  • Ferring Pharmaceuticals, Inc.
  • Janssen Biotech, Inc.
  • Protagonist Therapeutics Inc.
  • Lycera Corp.
  • Pepscan Therapeutics
  • N30 Pharmaceuticals
  • GlycoMar Limited
  • RaQualia Pharma Inc.
  • Atlantic Healthcare Limited
  • Sigmoid Pharma Ltd.
  • ProNoxis AB
  • ProtAb Ltd
  • Complix NV
  • Amakem NV
  • Delenex Therapeutics AG
  • Creabilis SA
  • SK Biopharmaceuticals Co., Ltd.
  • ReveraGen BioPharma, Inc.
  • ChironWells GmbH
  • GT Biologics Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • MultiStem
  • vidofludimus
  • KRP-203
  • YKP-GI
  • vatelizumab
  • abrilumab
  • CR-3294
  • BL-7040
  • AKP-001
  • STD-07
  • FE-301
  • ZP-1848
  • bertilimumab
  • GSK-1070806
  • SP-333
  • AQX-1125
  • HF-1020
  • CAT-1004
  • MT-1303
  • E-6011
  • VEN-120
  • AKP-001
  • GLPG-1205
  • FX-125-L
  • BL-5040
  • CRACM Channel Inhibitors
  • CGEN-855-A
  • CGEN-855-B
  • cobiprostone
  • ONX-0914
  • CGEN-25007
  • AGS-010
  • Kv1.3 Program
  • CTLA-4 X mono-IL-10
  • AFM-15
  • RQ-00202730
  • PTK-RA-01
  • PAR-2 Program
  • INO-763
  • INO-741
  • Cx-602
  • MRX-5
  • Soluble Beta Glucan
  • GED-0414
  • GED-0507
  • MSX-122
  • NX-002等

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6950IDB

Summary

Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2015', provides an overview of the Inflammatory Bowel Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Inflammatory Bowel Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Inflammatory Bowel Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Inflammatory Bowel Disease Overview
  • Therapeutics Development
  • Inflammatory Bowel Disease - Therapeutics under Development by Companies
  • Inflammatory Bowel Disease - Therapeutics under Investigation by Universities/Institutes
  • Inflammatory Bowel Disease - Pipeline Products Glance
  • Inflammatory Bowel Disease - Products under Development by Companies
  • Inflammatory Bowel Disease - Products under Investigation by Universities/Institutes
  • Inflammatory Bowel Disease - Companies Involved in Therapeutics Development
  • Inflammatory Bowel Disease - Therapeutics Assessment
  • Drug Profiles
  • Inflammatory Bowel Disease - Recent Pipeline Updates
  • Inflammatory Bowel Disease - Dormant Projects
  • Inflammatory Bowel Disease - Dormant Projects
  • Inflammatory Bowel Disease - Discontinued Products
  • Inflammatory Bowel Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Inflammatory Bowel Disease, H2 2015
  • Number of Products under Development for Inflammatory Bowel Disease - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Development by Companies, H2 2015 (Contd..10)
  • Number of Products under Development by Companies, H2 2015 (Contd..11)
  • Number of Products under Development by Companies, H2 2015 (Contd..12)
  • Number of Products under Development by Companies, H2 2015 (Contd..13)
  • Number of Products under Development by Companies, H2 2015 (Contd..14)
  • Number of Products under Development by Companies, H2 2015 (Contd..15)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Development by Companies, H2 2015 (Contd..13)
  • Products under Development by Companies, H2 2015 (Contd..14)
  • Products under Development by Companies, H2 2015 (Contd..15)
  • Products under Development by Companies, H2 2015 (Contd..16)
  • Products under Development by Companies, H2 2015 (Contd..17)
  • Products under Development by Companies, H2 2015 (Contd..18)
  • Products under Development by Companies, H2 2015 (Contd..19)
  • Products under Development by Companies, H2 2015 (Contd..20)
  • Products under Development by Companies, H2 2015 (Contd..21)
  • Products under Development by Companies, H2 2015 (Contd..22)
  • Products under Development by Companies, H2 2015 (Contd..23)
  • Products under Development by Companies, H2 2015 (Contd..24)
  • Products under Development by Companies, H2 2015 (Contd..25)
  • Products under Development by Companies, H2 2015 (Contd..26)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Inflammatory Bowel Disease - Pipeline by 4D Pharma Plc, H2 2015
  • Inflammatory Bowel Disease - Pipeline by 4SC AG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by AB Science SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by AbbVie Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Advinus Therapeutics Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Aerpio Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Akari Therapeutics, Plc, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Alba Therapeutics Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by AlbireoPharma, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Alfa Wassermann S.p.A, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Allozyne, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Altheus Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Alvine Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Am-Pharma B.V., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Amakem NV, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Amgen Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Amorepacific Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Amyra Biotech AG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Apogee Biotechnology Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Ardelyx, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Argos Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by AskAt Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Astellas Pharma Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Atlantic Healthcare Plc, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Avaxia Biologics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Axxam SpA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Basilea Pharmaceutica AG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by BioAtla, LLC, H2 2015
  • Inflammatory Bowel Disease - Pipeline by BIOCAD, H2 2015
  • Inflammatory Bowel Disease - Pipeline by BioLineRx, Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by BioLingus AG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Bionovis SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Biotec Pharmacon ASA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by BioTherapeutics Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Blueberry Therapeutics Ltd, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Calypso Biotech SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Celgene Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Cell2B S.A. , H2 2015
  • Inflammatory Bowel Disease - Pipeline by Cellceutix Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Celltrion, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by ChemoCentryx, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by ChironWells GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
  • Inflammatory Bowel Disease - Pipeline by CLL Pharma, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Commence Bio, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Creabilis SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Cytori Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by DBV Technologies S.A., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Delenex Therapeutics AG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Dr. Falk Pharma GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Effimune SAS, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Eisai Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Eli Lilly and Company, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Eligo Bioscience S.A.S., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Emergent BioSolutions Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Enceladus Pharmaceuticals BV, H2 2015
  • Inflammatory Bowel Disease - Pipeline by enGene, Inc, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Enterome Bioscience SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Enzo Biochem, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Ferring International Center S.A., H2 2015
  • Inflammatory Bowel Disease - Pipeline by FibroGen, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Flexion Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Galapagos NV, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Genentech, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Genfit SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Genor BioPharma Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Gilead Sciences, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by GlycoMar Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by GW Pharmaceuticals Plc, H2 2015
  • Inflammatory Bowel Disease - Pipeline by iCo Therapeutics Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Immune Response BioPharma, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by ImmusanT, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by InDex Pharmaceuticals AB, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Innate Pharma SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Innovent Biologics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by INOXIA Lifesciences GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Intas Pharmaceuticals Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Intrexon Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Invion Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Jenrin Discovery, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Johnson & Johnson, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Jyant Technologies, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Kezar Life Sciences, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Kineta, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Kymab Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by La Jolla Pharmaceutical Company, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Lead Pharma Holding B.V., H2 2015
  • Inflammatory Bowel Disease - Pipeline by LIPID THERAPEUTICS GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Lpath, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Lycera Corp., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Mabion SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Mabtech Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Medestea Research & Production S.p.A., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Medgenics Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by MedImmune, LLC, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Merck & Co., Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Mesoblast Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by MetrioPharm AG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Momenta Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Morphotek, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Mycenax Biotech Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Neovacs SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Nivalis Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Novozymes A/S, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Ocata Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Oncobiologics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Oncodesign SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Opsona Therapeutics Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Palatin Technologies, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Pepscan Therapeutics, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Pfenex Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Pfizer Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Plexxikon Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Pluristem Therapeutics Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Principia Biopharma Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by ProtAb Ltd, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Protagonist Therapeutics Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Provid Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Qu Biologics Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Rebiotix Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Receptos, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by RedHill Biopharma Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by ReveraGen BioPharma, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Salix Pharmaceuticals Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Sandoz International GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Saniona AB, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Sanofi, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Sareum Holdings Plc, H2 2015
  • Inflammatory Bowel Disease - Pipeline by SATT Nord, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Selexys Pharmaceuticals Corporation, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Seres Therapeutics, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Sigmoid Pharma Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Sitari Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Soligenix, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Spherium Biomed S.L., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Stelic Institute & Co., H2 2015
  • Inflammatory Bowel Disease - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Swecure AB, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Sylentis S.A., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Synergy Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Synovo GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Therapeutic Proteins International, LLC, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Therapix Biosciences Ltd, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Theravance Biopharma, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Tillotts Pharma AG, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Tiziana, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Tolerys SA, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Toray Industries, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Trino Therapeutics Limited, H2 2015
  • Inflammatory Bowel Disease - Pipeline by UCB S.A., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Ventria Bioscience, H2 2015
  • Inflammatory Bowel Disease - Pipeline by VG Life Sciences, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Virobay Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by vTv Therapeutics LLC, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Winston Pharmaceuticals, Inc., H2 2015
  • Inflammatory Bowel Disease - Pipeline by Xbrane Bioscience AB, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Zedira GmbH, H2 2015
  • Inflammatory Bowel Disease - Pipeline by Zyngenia, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Inflammatory Bowel Disease Therapeutics - Recent Pipeline Updates, H2 2015
  • Inflammatory Bowel Disease - Dormant Projects, H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..1), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..2), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..3), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..4), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..5), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..6), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..7), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..8), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..9), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..10), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..11), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..12), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..13), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..14), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..15), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..16), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..17), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..18), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..19), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..20), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..21), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..22), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..23), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..24), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..25), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..26), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..27), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..28), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..29), H2 2015
  • Inflammatory Bowel Disease - Dormant Projects (Contd..30), H2 2015
  • Inflammatory Bowel Disease - Discontinued Products, H2 2015
  • Inflammatory Bowel Disease - Discontinued Products (Contd..1), H2 2015
  • Inflammatory Bowel Disease - Discontinued Products (Contd..2), H2 2015
  • Inflammatory Bowel Disease - Discontinued Products (Contd..3), H2 2015
  • Inflammatory Bowel Disease - Discontinued Products (Contd..4), H2 2015

List of Figures

  • Number of Products under Development for Inflammatory Bowel Disease, H2 2015
  • Number of Products under Development for Inflammatory Bowel Disease - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top